Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Apollo Global Management Ord Shs (APO) Price & Performance

Amgen, Inc.Trade
Apollo Global Management Ord ShsTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Apollo Global Management Ord Shs — how do they compare? Amgen, Inc. trades at $415.98 (market cap $224.14B), while Apollo Global Management Ord Shs trades at $138.9 (market cap $82.84B). The key difference: Amgen, Inc. is far larger — about 2.7× Apollo Global Management Ord Shs's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.

AMGNAPO
Market Cap
$224.14B$82.84B
Sector
HealthFinancials
52-Week High
$417.20$152.70
52-Week Low
$271.18$100.30
Enterprise Value
$267.45B-$168.65B
Dividend Yield
2.43%1.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

Apollo Global Management Ord Shs

Apollo Global Management (APO) trades at $138.79, up 5.13% today, near its 52-week high. The stock shows a bullish technical trend with strong analyst support, including 23 buy ratings and a consensus price target of $151.50. Recent Q2 2026 earnings of $2.11 per share missed estimates, but revenue growth and record assets under management of $1.05 trillion highlight operational strength. The company continues expanding in AI infrastructure deals, as noted in recent news.

Outlook remains positive given robust fundraising and perpetual capital growth, though risks include expense pressures and market volatility. The high P/E ratio of 49.92 suggests premium valuation, requiring sustained earnings growth to justify upside. Investors should weigh strong institutional sentiment against execution risks in a competitive asset management landscape.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Apollo Global Management Ord Shs

Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit

Read more on APO